New and emerging medical therapies in Parkinsons disease

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 7, 2016, Pages 895-909

  Lotia, Mitesh ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

amantadine; disease modifying therapies; Emerging therapies; levodopa; levodopa induced dyskinesia; neuroprotection; nondopaminergic drug; Parkinson; synuclein

Indexed keywords

ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DIPRAGLURANT; DISEASE MODIFYING DRUG; DM 1992; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ELTOPRAZINE; ISTRADEFYLLINE; LEVODOPA; MAVOGLURANT; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; PRELADENANT; TOZADENANT; UNCLASSIFIED DRUG; XP 21279; ZONISAMIDE; CARBIDOPA;

ANTIDYSKINETIC EFFECT; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; GEL; HUMAN; LEVODOPA-INDUCED DYSKINESIA; MICROTABLET; MULTICENTER STUDY (TOPIC); NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMATE MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TABLET; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION ROUTE; QUALITY OF LIFE;

ANTIPARKINSON AGENTS; CARBIDOPA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 84958749002     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1149163     Document Type: Review

References (122)

1. Parkinson J. An essay on the shaking palsy. Chicago: American Medical Assoc. Press; 1817.
2. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinsons disease. Curr Opin Neurol. 2012 Aug; 25 (4): 448-459.
3. Okun MS. Deep-brain stimulation-entering the era of human neural-network modulation. New England J Med. 2014; 371 (15): 1369-1373.
4. Metman LV, Slavin KV. Advances in functional neurosurgery for Parkinsons disease. Mov Disord. 2015; 30 (11): 1461-1470.
5. Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease[mdash]past insights and future potential. Nat Rev Neurol. 2015; 11 (9): 492-503.
6. Jankovic J, Poewe W. Therapies in Parkinsons disease. Curr Opin Neurol. 2012 Aug; 25 (4): 433-447.
7. Rascol O, PerezLloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015; 30 (11): 1451-1460.
8. Capildeo R. Implications of the 5-year CR FIRST trial. Sinemet CR five-year international response fluctuation study. Neurology. 1998 Jun; 50 (6 Suppl 6): S15-S17. discussion S44-8.
9. Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinsons disease. Lancet Neurol. 2015 Jun; 14 (6): 625-639.
10. Stocchi F, Quinn NP, Barbato L, et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1994 Feb; 17 (1): 38-44.
11. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopaLevodopa (IPX066) compared with immediate-release carbidopaLevodopa in patients with Parkinsons disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr; 12 (4): 346-356.
12. Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinsons disease. Parkinsonism Relat Disord. 2014; 20 (2): 142-148.
13. Lewitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinsons disease. Mov Disord. 2014; 29 (1): 75-82.
14. Verhagen Metman L, Stover N, Chen C, et al. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinsons disease. Mov Disord. 2015; 30 (9): 1222-1228.
15. Nyholm D, Lewander T, Gomes-Trolin C, et al. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol. 2012; 35 (3): 111-117.
16. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinsons disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014; 13 (2): 141-149.
17. Giladi N, Caraco Y, Gureritch T, et al. Pharmacokinetics and safety of ND0612L (levodopa/carbidopa for subcutaneous infusion): results from a phase II study in moderate to severe Parkinsons disease (P1.187). Neurology. 2015 Apr 6; 84 (14 Suppl):1187.
18. LeWitt PA, Saint-Hilaire MH, Grosset DG, et al. Inhaled levodopa (CVT-301) provides rapid motor improvements after administration to Parkinsons disease patients when OFF [abstract]. Mov Disord. 2015; 30: S1-S567.
19. Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopaLevodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec; 20 (12): 1335-1340.
20. Waters CH, Nausieda P, Dzyak L, et al. Long-term treatment with extended-release carbidopaLevodopa (IPX066) in early and advanced Parkinsons disease: a 9-month openLabel extension trial. CNS Drugs. 2015 Apr; 29 (4): 341-350.
21. Lewitt PA, Ellenbogen A, Chen D, et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol. 2012 May-Jun; 35 (3): 103-110.
22. Chen R-N, Ho H-O, Yu C-Y, et al., Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. Eur J Pharm Sci. 2010; 39 (1-3): 82-89.
23. Chen C, Cowles VE, Sweeney M, et al. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 2012 Mar-Apr; 35 (2): 67-72.
24. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinsons disease: A prospective study using single-dose challenges. Mov Disord. 2005; 20 (2): 151-157.
25. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinsons disease: final 12-month, openLabel results. Mov Disord. 2015; 30 (4): 500-509.
26. Zibetti M, Merola A, Ricchi V, et al. Long-term duodenal levodopa infusion in Parkinsons disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013 Jan; 260 (1): 105-114.
27. Calandrella D, Romito LM, Elia AE, et al. Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology. 2015 Apr 21; 84 (16): 1669-1672.
28. Buongiorno M, Antonelli F, Camara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015 Aug; 21 (8): 871-876.
29. Caraco Y, Oren S, Lewitt PA. Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD). June 2013 ed. MDS 17th International Congress of Parkinsons Disease and Movt Disord. 2013; 28 (Suppl 1): 452.
30. Freed MI, Batycky R, Merica E. Safety, tolerability and levodopa pharmacokinetics following inhaled administration of CVT-301, a levodopa dry powder aerosol, in healthy, adult subjects [abstract]. Mov Disord. 2013; 28 (Suppl 1):430.
31. Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinsons disease with motor fluctuations. Mov Disord. 2014; 29 (2): 229-237.
32. Ferreira JJ, Rocha JF, Falcaõ A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinsons disease. Eur J Neurol. 2015; 22 (5): 815-825.
33. Mizuno Y, Kondo T. The Japanese istradefylline study G. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinsons disease. Mov Disord. 2013; 28 (8): 1138-1141.
34. Hauser RA, Stocchi F, Rascol O. Two phase-3 randomized clinical trials of adjunctive therapy with preladenant in Parkinsons disease. JAMA Neurol. 2015; 72 (10): 221-229.
35. Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinsons disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014; 13 (8): 767-776.
36. Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 2012 Jul 10; 79 (2): 163-169.
37. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. 2013 Nov; 28 (13): 1838-1846.
38. Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinsons disease (EASED Study). Mov Disord. 2015; 30 (6): 788-795.
39. Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinsons disease. Movt Disord. 2014; 29 (10): 1273-1280.
40. Bial. Opicapone significantly improves OFF-time in fluctuating Parkinsons Disease patients as add-on to levodopa. 2015. Available from: https://www.bial.com/en/pressroom.138/news.140/opicaponesignificantlyimprovesoff-time.a494.html
41. Stibe CMH, Kempster PA, Lees AJ, et al. Subcutaneous apomorphine in parkinsonian ON-OFF oscillations. Lancet. 1988; 331 (8582): 403-406.
42. Garciá Ruiz PJ, Sesar Ignacio Á, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinsons disease with motor fluctuations: a multicenter study. Movt Disord. 2008; 23 (8): 1130-1136.
43. Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinsons disease. Expert Rev Neurother. 2015; 15 (7): 723-732.
44. Trenkwalder C, Chaudhuri KR, Garciá Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinsons disease-clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023-1030.
45. Dewey RB Jr, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001; 58 (9): 1385-1392.
46. Grosset KA, Malek N, Morgan F, et al. Inhaled apomorphine in patients with on-off fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013; 3 (1): 31-37.
47. Grosset KA, Malek N, Morgan F, et al. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing off periods in patients with established Parkinsons disease. Eur J Neurol. 2013 Nov; 20 (11): 1445-1450.
48. Pinna A. Adenosine A2A receptor antagonists in Parkinsons disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May; 28 (5): 455-474.
49. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003 Aug 12; 61 (3): 297-303.
50. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinsons disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008; 63 (3): 295-302.
51. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008 Jun 3; 70 (23): 2233-2240.
52. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinsons disease on levodopa with motor fluctuations. Mov Disord. 2008; 23 (15): 2177-2185.
53. Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinsons disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012; 18 (2): 178-184.
54. Zhu C, Wang G, Li J, et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinsons disease: a meta-analysis. Neurol Res. 2014 Nov; 36 (11): 1028-1034.
55. Kondo T, Mizuno Y. Japanese istradefylline study G. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015 Mar-Apr; 38 (2): 41-46.
56. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinsons disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011; 10 (3): 221-229.
57. Barret O, Hannestad J, Alagille D, et al. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. J Nuclear Medicine: Official Publication, Soc Nucl Med. 2014 Oct; 55 (10): 1712-1718.
58. Black KJ, Koller JM, Campbell MC, et al. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci. 2010 Dec 1; 30 (48): 16284-16292.
59. Black KJ, Campbell MC, Dickerson W, et al. A randomized, double-blind, placebo-controlled cross-over trial of the adenosine 2a antagonist SYN115 in Parkinson disease. Neurology. 2010;74(Suppl 2):A317.
60. Savola J-M, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTPLesioned primate model of Parkinsons disease. Mov Disord. 2003; 18 (8): 872-883.
61. Johnston TH, Fox SH, Piggott MJ, et al. The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov Disord. 2010; 25 (13): 2084-2093.
62. Dimitrova T, Bara-Jimenez W, Savola J-M. Alpha-2 adrenergic antagonist effects in Parkinsons disease. Movt Disord. 2009; 24 (S1): S1-S653.
63. Ramlackhansingh AF, Bose SK, Ahmed I, et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011 May 24; 76 (21): 1811-1816.
64. Finlay C, Duty S. Therapeutic potential of targeting glutamate receptors in Parkinsons disease. J Neural Transm. 2014; 121 (8): 861-880.
65. Morin N, Di Paolo T. Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTPLesioned monkeys: brain glutamate biochemical correlates. Front Neurol. 2014; 5: 144.
66. Calon F, Rajput AH, Hornykiewicz O, et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinsons disease. Neurobiol Dis. 2003; 14 (3): 404-416.
67. Ouattara B, Grégoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging. 2011; 32 (7): 1286-1295.
68. Adamas Announces Positive TopLine Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinsons Disease. [Internet] 2015 [cited 23 December 2015]. Available from: http://ir.adamaspharma.com/releasedetail.cfmReleaseID=948032
69. Fox SH, Katzenschlager R, Lim S-Y, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinsons disease. Mov Disord. 2011; 26 (S3): S2-S41.
70. Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineLesioned macaque model of Parkinsons disease. J Pharmacol Exp Ther. 2010 Jun; 333 (3): 865-873.
71. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord. 2011; 26 (7): 1243-1250.
72. Kumar R, Hauser RA, Mostillo J, et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinsons disease patients. Int J Neurosci. 2016;126(1):20-24.
73. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis. 2010; 39 (3): 352-361.
74. Bezard E, Pioli EY, Li Q, et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord. 2014; 29 (8): 1074-1079.
75. Tison F, Durif F, Corvol JC, et al. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinsons disease (PD) patients with levodopa-induced dyskinesia (LID)(S23. 004). Neurology. 2013; 80 (Meeting Abstracts 1): S23-004.
76. Kobylecki C, Burn DJ, Kass-Iliyya L, et al. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinsons disease. Parkinsonism Relat Disord. 2014 Apr; 20 (4): 452-455.
77. Huot P, Johnston TH, Koprich JB, et al. The pharmacology of l-DOPA-induced dyskinesia in Parkinsons disease. Pharmacol Rev. 2013 January 1; 65 (1): 171-222.
78. Cenci MA, Ohlin KE, Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinsons disease. CNS Neurol Disord Drug Targets. 2011 Sep 1; 10 (6): 670-684.
79. Bezard E, Tronci E, Pioli EY, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movt Disord. 2013; 28 (8): 1088-1096.
80. Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinsons disease: a dose-finding study. Brain. 2015 Apr; 138 (Pt 4): 963-973.
81. AlDakheel A, Kalia L, Lang A. Pathogenesis-targeted, disease-modifying therapies in parkinson disease. Neurotherapeutics. 2014; 11 (1): 6-23.
82. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011 Jan; 68 (1): 22-30.
83. Kalia LV, Lang AE. Parkinsons disease. Lancet. April 2015;386(9996):890-912.
84. Schapira AHV, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinsons disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013; 12 (8): 747-755.
85. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinsons disease (STEADY-PD). Movt Disord. 2013; 28 (13): 1823-1831.
86. Investigators NETiPDF-Z. Pioglitazone in early Parkinsons disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015; 14 (8): 795-803.
87. Writing Group for the NETiPDI. Effect of creatine monohydrate on clinical progression in patients with parkinson disease: a randomized clinical trial. JAMA. 2015; 313 (6): 584-593.
88. The Parkinson Study Group QEI. A randomized clinical trial of high-dosage coenzyme q10 in early parkinson disease: no evidence of benefit. JAMA Neurol. 2014; 71 (5): 543-552.
89. Warren Olanow C, Bartus RT, Baumann TL, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015; 78 (2): 248-257.
90. Parkinson Study Group PI. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007 Oct 9; 69 (15): 1480-1490.
91. LeWitt PA. Deprenyls effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Cardiol Suppl. 1991; 136: 79-86.
92. Ascherio A, LeWitt PA, Xu K, et al. URate as a predictor of the rate of clinical decline in parkinson disease. Arch Neurol. 2009; 66 (12): 1460-1468.
93. The Parkinson Study Group S-PDI. Inosine to increase serum and cerebrospinal fluid urate in parkinson disease: a randomized clinical trial. JAMA Neurol. 2014; 71 (2): 141-150.
94. Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinsons disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015; 14 (8): 855-866.
95. Prothena. PRX002 for Parkinsons disease and other related synucleinopathies. 2015 [cited 2015 Aug 25[. Available from: http://www.prothena.com/pipeline/prx002-for-parkinsons-disease.
96. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003 Jan 14; 60 (1): 69-73.
97. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006; 59 (3): 459-466.
98. Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinsons disease patients. J Neurol Sci. 2013; 324 (1-2): 140-148.
99. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinsons disease. Prog Neurobiol. 2005 Sep-Oct; 77 (1-2): 128-138.
100. Alavian KN, Jeddi S, Naghipour SI, et al. The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed. J Biomed Sci. 2014; 21: 27.
101. Chu Y, Le W, Kompoliti K, et al. Nurr in Parkinsons disease and related disorders. J Comp Neurol. 2006 Jan 20; 494 (3): 495-514.
102. Decressac M, Kadkhodaei B, Mattsson B, et al. alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012 Dec 5; 4 (163): 163-56.
103. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009 Apr 3; 137 (1): 47-59.
104. Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinsons disease. Proc Natl Acad Sci USA. 2015 Jul 14; 112 (28): 8756-8761.
105. Smith GA, Rocha EM, Rooney T, et al. A nurr1 agonist causes neuroprotection in a Parkinsons disease lesion model primed with the tollLike receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS ONE. 2015; 10 (3): e0121072.
106. Charbel M, Pagan F. Cancer drug improved cognition and motor skills in small Parkinsons clinical trial. 2015. Available from: http://www.medstargeorgetown.org/2015/10/17/cancer-drug-improved-cognition-and-motor-skills-in-small-parkinsons-clinical-trial/#
107. Murata M, Hasegawa K, Kanazawa I. Japan zonisamide on PDSG Zonisamide Improves Motor Function Parkinson Disease: Randomized, Double-Blind Study. Neurology. 2007 Jan 2; 68 (1): 45-50.
108. Iijima M, Osawa M, Kobayashi M, et al. Efficacy of zonisamide in a case of Parkinsons disease with intractable resting and re-emergent tremor. Eur J Neurol. 2011; 18 (4): e43-e44.
109. Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinsons disease: a randomized, double-blind study. Mov Disord. 2015; 30 (10): 1343-1350.
110. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014; 83 (4): 328-335.
111. Ellenbogen AL, Bardram KM, Chang CT, et al. A phase II, double blind, randomized placebo-controlled 4-way crossover study to evaluate the relative efficacy and safety of OC oral solution (oxybutynin and clonidine) for sialorrhea in patients with Parkinsons disease [abstract]. Mov Disord. 2013;28(Suppl 1): 494.
112. Thobois S, Lhommeé E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013; 136 (5): 1568-1577.
113. Sawada H, Oeda T. Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinsons disease (EDAP). BMJ Open. 2013; 3 (9): e003533.
114. Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinsons disease. Parkinsonism Relat Disord. 2015; 21 (5): 514-520.
115. Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinsons disease (nOH306B). Mov Disord. 2015; 30 (5): 646-654.
116. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinsons disease (NOH306A). J Parkinsons Dis. 2014; 4 (1): 57-65.
117. Lloret SP, Nano G, Carrosella A, et al. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinsons disease patients. J Neurol Sci. 2011; 310 (1-2): 248-250.
118. Perissinotto MC, DAncona CA, Lucio A, et al. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Continence Nurs. 2015 Jan-Feb; 42 (1): 94-99.
119. Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinsons disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurology, Neurosurg Psychiatry. 2014 June 1; 85 (6): 668-674.
120. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinsons disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014; 383 (9916): 533-540.
121. Thenganatt M, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014; 71 (4): 499-504.
122. Feng Y, Jankovic J, Wu Y-C. Epigenetic mechanisms in Parkinsons disease. J Neurol Sci. 2015; 349 (1-2): 3-9.